The April 2026 final order from the Acting Attorney General immediately moved only FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, while recreational marijuana remained Schedule I. An expedited DEA administrative hearing on broader rescheduling to Schedule III ran from June 29 to July 15, 2026, with selected participants largely opposed and post-hearing briefs due by August 17. The process now awaits an administrative law judge recommendation and final agency action, with no statutory deadline. Legal challenges to the partial order and obligations under the Single Convention on Narcotic Drugs continue to shape timelines. Trader pricing reflects these procedural hurdles and the limited scope of completed changes rather than full rescheduling.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$803,423 Vol.
September 30
5%
December 31
18%
$803,423 Vol.
September 30
5%
December 31
18%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...The April 2026 final order from the Acting Attorney General immediately moved only FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, while recreational marijuana remained Schedule I. An expedited DEA administrative hearing on broader rescheduling to Schedule III ran from June 29 to July 15, 2026, with selected participants largely opposed and post-hearing briefs due by August 17. The process now awaits an administrative law judge recommendation and final agency action, with no statutory deadline. Legal challenges to the partial order and obligations under the Single Convention on Narcotic Drugs continue to shape timelines. Trader pricing reflects these procedural hurdles and the limited scope of completed changes rather than full rescheduling.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions